熱門資訊> 正文
木薯科学公司将支付3125万美元和解证券集体诉讼
2025-12-23 21:38
- Cassava Sciences (SAVA) announced on Tuesday that it agreed to pay $31.25M to settle a class action lawsuit pending in a Texas District Court over the company’s alleged violations of the federal securities laws.
- The case filed in the U.S. District Court for the Western District of Texas, Austin Division, in 2021 relied on allegations contained in Citizen Petitions submitted to the FDA regarding Cassava’s (SAVA) lead asset, simufilam.
- In November 2024, the company suffered a late-stage trial setback for the once high-flying oral therapy targeted at Alzheimer's disease.
- “The settlement is not an admission of fault or wrongdoing by the Company,” Cassava (SAVA) said, adding that it has recorded a $31.25M provision in Q2 2025 to recognize a potential loss contingency related to the case.
More on Cassava Sciences
- Cassava Sciences: Fundamentals Update After Big Move On Insider Purchases
- Cassava Sciences drops on delay for epilepsy study
- Cassava Sciences hit with FDA request for more data on simufilam trial
- Seeking Alpha’s Quant Rating on Cassava Sciences
- Historical earnings data for Cassava Sciences
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
